SHELTON, Connecticut,
April 1, 2020 /PRNewswire/
-- International medical imaging IT and cybersecurity
company Sectra (STO: SECT B) has received a 510(k)
clearance by the US Food & Drug Administration (FDA). The
clearance applies for Sectra Digital Pathology Module, the key
component of Sectra's pathology solution, when used together with
Leica Biosystems' scanner AT2 DX. This enables US healthcare
providers to use Sectra's digital pathology solution for primary
diagnostics. The solution makes it possible to move towards fully
integrated diagnostics, which is especially important in complex
cancer cases.
"I'm excited that with the FDA approval, we are now able to
offer US healthcare providers a digital pathology offering with a
proven track-record of use for full-scale primary diagnostics and
large volumes," says Mikael Anden,
President, Sectra Inc. "Our solution makes it possible for
pathologists across the country to continue their important work
from home without the need for a microscope. We look forward to
providing uninterrupted pathology reading in these challenging
times. This approval is an exciting and important step forward for
pathology and cancer care in the US."
Sectra's digital pathology solution is already used in the US
for research and tumor boards and can now also be used in primary
diagnostics. With digital images of tissue samples instead of
physical glass slides, pathologists gain instant access to
current and historical images and related data as well as to
digital tools for reviewing the images. Digital access also
facilitates efficient second opinions, remote reading, specialist
consultations and makes integrated diagnostics possible.
The digital pathology solution is a component of Sectra's
enterprise imaging offering, of which all components are built on
the same technical platform. This allows healthcare providers to
use a single solution for their medical imaging needs across all
specialties, enabling integrated diagnostics. A deeper cooperation
and ability to access other departmental images and information
contributes to improved efficiency and patient care. This is
especially important for complex cases where both radiology and
pathology play key roles. Instant access to digital pathology
images, side by side with radiology or other images, enables more
efficient discussions and the ability to give detailed descriptions
of findings.
"Pathology is the next huge digitization of healthcare. The use
of glass slides limits growth in today's increasingly digital
environment, especially in consolidated health care systems where
potential synergies cannot be reached unless pathology is
digitized. Our solution opens up new opportunities in the US where
we can point to our successes in Europe in large production centers," says Dr.
Torbjörn Kronander, President and CEO of Sectra.
Watch this video to learn more about how digital pathology
can enable increased efficiency and higher precision for the
pathologists.
About Sectra Imaging IT Solutions
With more than 30 years of innovation and 2,000 installations
worldwide, Sectra is a leading global provider of imaging IT
solutions that support healthcare in achieving patient-centric
care. Sectra offers an enterprise imaging solution comprising PACS
for imaging-intense departments (radiology, pathology, cardiology,
orthopedics), VNA, and share and collaborate solutions. Read more
about Sectra and why Sectra PACS is "Best in KLAS" for a seventh
consecutive year at https://medical.sectra.com.
Contacts:
Andrea Sowitch, Vice President of
Marketing
Sectra, Inc.
E-mail: andrea.sowitch@sectra.com
Phone: +1-203-925-0899 ext. 268
Torbjörn Kronander, President and CEO
Sectra AB
E-mail: torbjorn.kronander@sectra.se
Phone: +46-705-23-5227
View original
content:http://www.prnewswire.com/news-releases/fda-clearancesectras-digital-pathology-solution-available-for-primary-diagnostics-and-remote-reading-in-the-us-301033242.html
SOURCE Sectra, Inc